Role of 18F-FDG PET/CT in the assessment of therapy response and clinical outcome in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors or immunotherapy-Reference-Cited by-同舟云学术

Role of 18F-FDG PET/CT in the assessment of therapy response and clinical outcome in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors or immunotherapy

Published:2022-04-01 Issue:6 Volume:43 Page:701-709
ISSN:0143-3636
Container-title:Nuclear Medicine Communications
language:en
Short-container-title:

Author:

Tatar Gamze,Alçin Göksel,Şengül Samanci Nilay,Erol Fenercioglu Özge,Beyhan Ediz,Çermik Tevfik Fikret

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Reference26 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.;Ferlay;Int J Cancer,2015

2. Renal cell carcinoma.;Rini;Lancet,2009

3. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.;Ferlay;Eur J Cancer,2013

4. Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma.;Reed;Expert Rev Anticancer Ther,2019

5. Nivolumab in renal cell carcinoma: current trends and future perspectives.;Ochoa;J Kidney Cancer VHL,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early response assessment to targeted therapy in metastatic clear cell renal cancer using 68Ga-PSMA-11 PET/CT and comparison with CECT: a feasibility study;Clinical and Translational Imaging;2024-04-09

2. The evolution of PET imaging in renal, bladder, upper urinary tract urothelial, testicular and penile carcinoma – Today’s impact, tomorrow’s potential;Expert Review of Medical Devices;2023-12-12

3. SEOM SOGUG clinical guideline for treatment of kidney cancer (2022);Clinical and Translational Oncology;2023-08-09